Brooks Laboratories Limited (BROOKS.BO)
INR 162.3
(1.98%)
INR 162.3
(1.98%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 65.62 Million INR | 737.89% |
| 2022 | 12.59 Million INR | -91.19% |
| 2021 | 142.94 Million INR | -34.43% |
| 2020 | 218 Million INR | 39.25% |
| 2019 | 156.55 Million INR | 63.38% |
| 2018 | 95.82 Million INR | 6.12% |
| 2017 | 90.3 Million INR | -49.64% |
| 2016 | 179.33 Million INR | -23.37% |
| 2015 | 234.03 Million INR | 16.54% |
| 2014 | 200.81 Million INR | -10.73% |
| 2013 | 224.93 Million INR | 9.85% |
| 2012 | 204.77 Million INR | 16.43% |
| 2011 | 175.88 Million INR | 31.8% |
| 2010 | 133.45 Million INR | 34.28% |
| 2009 | 99.37 Million INR | 23.49% |
| 2008 | 80.47 Million INR | 5.92% |
| 2007 | 75.97 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 21.54 Million INR | -5.08% |
| 2023 Q1 | 15.07 Million INR | 122.0% |
| 2023 Q2 | 68.54 Million INR | 354.71% |
| 2023 Q3 | 62.88 Million INR | -8.27% |
| 2023 Q4 | 22.7 Million INR | -63.9% |
| 2023 FY | 105.53 Million INR | 737.89% |
| 2022 Q1 | 9.64 Million INR | 122.55% |
| 2022 Q2 | 33.44 Million INR | 246.68% |
| 2022 Q3 | 38.01 Million INR | 13.69% |
| 2022 Q4 | -68.51 Million INR | -280.21% |
| 2022 FY | 12.59 Million INR | -91.19% |
| 2021 FY | 142.94 Million INR | -34.43% |
| 2021 Q2 | 57.44 Million INR | -29.36% |
| 2021 Q4 | -42.77 Million INR | -200.79% |
| 2021 Q3 | 42.44 Million INR | -26.13% |
| 2021 Q1 | 81.33 Million INR | 498.96% |
| 2020 FY | 218 Million INR | 39.25% |
| 2020 Q1 | 48.57 Million INR | 879.32% |
| 2020 Q2 | 124.36 Million INR | 156.03% |
| 2020 Q3 | 65.71 Million INR | -47.16% |
| 2020 Q4 | -20.38 Million INR | -131.02% |
| 2019 Q4 | -6.23 Million INR | -110.14% |
| 2019 Q2 | 43.6 Million INR | -24.46% |
| 2019 Q3 | 61.45 Million INR | 40.93% |
| 2019 FY | 156.55 Million INR | 63.38% |
| 2019 Q1 | 57.72 Million INR | 375.61% |
| 2018 Q3 | 50.82 Million INR | 14.54% |
| 2018 FY | 95.82 Million INR | 6.12% |
| 2018 Q2 | 44.37 Million INR | 105.73% |
| 2018 Q1 | 21.56 Million INR | -58.52% |
| 2018 Q4 | -20.94 Million INR | -141.21% |
| 2017 Q3 | 55.67 Million INR | 65.57% |
| 2017 Q1 | 22.05 Million INR | -44.1% |
| 2017 FY | 90.3 Million INR | -49.64% |
| 2017 Q4 | 51.99 Million INR | -6.61% |
| 2017 Q2 | 33.62 Million INR | 52.47% |
| 2016 FY | 179.33 Million INR | -23.37% |
| 2016 Q4 | 39.45 Million INR | -19.7% |
| 2016 Q3 | 49.13 Million INR | -10.26% |
| 2016 Q1 | 65.33 Million INR | -17.42% |
| 2016 Q2 | 54.75 Million INR | -16.2% |
| 2015 FY | 234.03 Million INR | 16.54% |
| 2015 Q3 | 71.35 Million INR | 2.97% |
| 2015 Q2 | 69.29 Million INR | 36.11% |
| 2015 Q1 | 50.91 Million INR | 96.81% |
| 2015 Q4 | 79.11 Million INR | 10.88% |
| 2014 Q1 | 40.62 Million INR | 140.19% |
| 2014 Q4 | 25.86 Million INR | -62.76% |
| 2014 FY | 200.81 Million INR | -10.73% |
| 2014 Q2 | 64.86 Million INR | 59.69% |
| 2014 Q3 | 69.47 Million INR | 7.1% |
| 2013 Q2 | 81.56 Million INR | 27.7% |
| 2013 Q4 | 16.91 Million INR | -72.95% |
| 2013 FY | 224.93 Million INR | 9.85% |
| 2013 Q3 | 62.52 Million INR | -23.33% |
| 2013 Q1 | 63.86 Million INR | 85.8% |
| 2012 Q3 | 70.6 Million INR | 14.8% |
| 2012 Q2 | 61.5 Million INR | 60.57% |
| 2012 Q4 | 34.37 Million INR | -51.31% |
| 2012 Q1 | 38.3 Million INR | -4.5% |
| 2012 FY | 204.77 Million INR | 16.43% |
| 2011 Q2 | 48.9 Million INR | 0.0% |
| 2011 Q4 | 40.1 Million INR | -25.18% |
| 2011 FY | 175.88 Million INR | 31.8% |
| 2011 Q3 | 53.6 Million INR | 9.61% |
| 2010 FY | 133.45 Million INR | 34.28% |
| 2009 FY | 99.37 Million INR | 23.49% |
| 2008 FY | 80.47 Million INR | 5.92% |
| 2007 FY | 75.97 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Ajanta Pharma Limited | 21.06 Billion INR | 99.688% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | 95.784% |
| Sigachi Industries Limited | 2 Billion INR | 96.723% |
| Bal Pharma Limited | 770.19 Million INR | 91.48% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | 98.941% |
| Medico Remedies Limited | 262.14 Million INR | 74.968% |
| Lasa Supergenerics Limited | 121.02 Million INR | 45.782% |
| Venus Remedies Limited | 2.18 Billion INR | 96.993% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 110.893% |
| Alpa Laboratories Limited | 188.89 Million INR | 65.261% |
| Nectar Lifesciences Limited | 2.97 Billion INR | 97.792% |
| Shilpa Medicare Limited | 3.54 Billion INR | 98.15% |
| Aarti Drugs Limited | 8.31 Billion INR | 99.211% |
| Lupin Limited | 123.71 Billion INR | 99.947% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 99.958% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 99.948% |
| Windlas Biotech Limited | 1.33 Billion INR | 95.099% |
| Suven Life Sciences Limited | -200.79 Million INR | 132.68% |
| Eris Lifesciences Limited | 10.42 Billion INR | 99.371% |
| Valiant Laboratories Limited | -60.66 Million INR | 208.17% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 99.711% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | 92.38% |
| Ipca Laboratories Limited | 29.8 Billion INR | 99.78% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 98.224% |
| Achyut Healthcare Limited | 4.86 Million INR | -1249.928% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 99.975% |
| Bajaj HealthCare Limited | 1.47 Billion INR | 95.542% |
| RPG Life Sciences Limited | 2.48 Billion INR | 97.357% |
| Mankind Pharma Limited | 44.52 Billion INR | 99.853% |
| Laurus Labs Limited | 24.62 Billion INR | 99.733% |
| Piramal Pharma Limited | 24.47 Billion INR | 99.732% |
| Syncom Formulations (India) Limited | 942.39 Million INR | 93.037% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 99.86% |
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 99.755% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 99.905% |
| Unichem Laboratories Limited | 4.86 Billion INR | 98.651% |
| Sequent Scientific Limited | 2.97 Billion INR | 97.797% |
| Novartis India Limited | 1.32 Billion INR | 95.055% |
| Wanbury Limited | 1.73 Billion INR | 96.208% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 98.409% |
| Wockhardt Limited | 16.24 Billion INR | 99.596% |
| Themis Medicare Limited | 1.5 Billion INR | 95.637% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | 89.945% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 99.666% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 99.472% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 99.96% |
| Divi's Laboratories Limited | 32.44 Billion INR | 99.798% |
| NATCO Pharma Limited | 25.73 Billion INR | 99.745% |
| Gufic Biosciences Limited | 4.16 Billion INR | 98.426% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | 98.567% |
| Ind-Swift Limited | 2.17 Billion INR | 96.98% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 98.865% |
| FDC Limited | 8.33 Billion INR | 99.213% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | 65.952% |
| Granules India Limited | 16.79 Billion INR | 99.609% |
| Medicamen Biotech Limited | 495.49 Million INR | 86.757% |
| Alkem Laboratories Limited | 52.29 Billion INR | 99.875% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 98.945% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -350.078% |
| Megasoft Limited | 342.07 Million INR | 80.817% |
| ZIM Laboratories Limited | 1.26 Billion INR | 94.82% |
| Strides Pharma Science Limited | 14.38 Billion INR | 99.544% |
| Neuland Laboratories Limited | 8.24 Billion INR | 99.204% |
| Morepen Laboratories Limited | 6.16 Billion INR | 98.935% |
| Hikal Limited | 3.14 Billion INR | 97.912% |
| Indoco Remedies Limited | 6.04 Billion INR | 98.914% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 98.875% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | 89.424% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | 90.674% |
| Hester Biosciences Limited | 1.27 Billion INR | 94.848% |